Discovering, developing and commercializing novel biotechnologies that demonstrate significant potential for considerable medical breakthroughs.
Welcome to Sanguine Life Sciences
Sanguine Corporation is keenly focused on pioneering the development and commercialization of innovative perfluorocarbon-based therapies and medical devices. Its lead product, PHER-02, is an intravenous perfluorocarbon emulsion that is highly efficient at dissolving and delivering oxygen to tissues. More information on PHER-O2.